Skip to content

Human Phototoxicity Test

Human Phototoxicity Test

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02754102
Enrollment
35
Registered
2016-04-28
Start date
2016-05-03
Completion date
2016-05-06
Last updated
2017-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sunscreening Agents

Brief summary

To determine the phototoxic potential of a topically applied article in human subjects.

Interventions

OTHERSunscreen Spray- Liquid (BAY987516)

50 μl/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back.

Sponsors

Bayer
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* be male or female between the ages of 18 and 60 inclusive; * be lightly pigmented (Fitzpatrick Skin Type I, II, III); * have read and signed the written Informed Consent Form and have completed a HIPAA (Health Insurance Portability and Accountability Act) Authorization Form in conformance with 45CFR (Code of Federal Regulations ) Parts 160 and 164; * be in general good health as determined by the subject's medical history and in the discretion of the investigator.

Exclusion criteria

* have a visible sunburn; * have a history of sun hypersensitivity/photosensitivity or photosensitive dermatosis; * must not have a known sensitivity or allergy against any of the active and non-active ingredients of the test product. * have a history of allergies or sensitivities to cosmetics, toiletries or any dermatological products.

Design outcomes

Primary

MeasureTime frame
Intensity of skin reactions will be evaluated using the 5 point grading scaleUp to 48 hours

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026